These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10227461)

  • 1. Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG).
    Hjorth M; Holmberg E; Rödjer S; Turesson I; Westin J; Wislöff F
    Eur J Haematol; 1999 Apr; 62(4):271-7. PubMed ID: 10227461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.
    Johnsen HE; Klausen TW; Boegsted M; Lenhoff S; Gimsing P; Christiansen I; Gedde-Dahl T; Lindås R; Mellqvist UH;
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):290-6. PubMed ID: 20709667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
    Bladé J; San Miguel JF; Fontanillas M; Alcalá A; Maldonado J; García-Conde J; Conde E; Conzález-Brito G; Moro MJ; Escudero ML; Trujillo J; Pascual A; Rozman C; Estapé J; Montserrat E
    J Clin Oncol; 1996 Jul; 14(7):2167-73. PubMed ID: 8683251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective].
    Hjorth M; Lenhoff S; Turesson I; Westin J
    Lakartidningen; 2000 Oct; 97(41):4585-6, 4589-92. PubMed ID: 11107744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
    Björkholm M
    Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
    Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
    N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
    Lenhoff S; Hjorth M; Holmberg E; Turesson I; Westin J; Nielsen JL; Wislöff F; Brinch L; Carlson K; Carlsson M; Dahl IM; Gimsing P; Hippe E; Johnsen HE; Lamvik J; Löfvenberg E; Nesthus I; Rödjer S
    Blood; 2000 Jan; 95(1):7-11. PubMed ID: 10607678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
    Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
    Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
    Attal M; Harousseau JL; Stoppa AM; Sotto JJ; Fuzibet JG; Rossi JF; Casassus P; Maisonneuve H; Facon T; Ifrah N; Payen C; Bataille R
    N Engl J Med; 1996 Jul; 335(2):91-7. PubMed ID: 8649495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplants for multiple myeloma.
    Tricot G; Jagannath S; Vesole DH; Bracy D; Desikan KR; Siegel D; Barlogie B
    Leuk Lymphoma; 1996 Jun; 22(1-2):25-36. PubMed ID: 8724525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients.
    Scudla V; Bacovsky J; Indrak K; Kodouskova V; Vytrasova M; Faber E; Papajik T; Adam Z; Hajek R; Horak P; Martinek A;
    Hematol J; 2003; 4(5):351-7. PubMed ID: 14502261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
    N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.